A single dose should be administered to all infants <8 months of age born during or entering their first RSV season (typically starting October 1 through March 31 in most of the continental US). For most babies whose mothers received RSVpreF at 32-36 weeks of pregnancy where at least 14 days have elapsed between vaccine administration and birth, nirsevimab will not be indicated. Please see the Nirsevimab Administration Visual Guide to help determine if and what dose is needed.
In addition to mother’s vaccination status, eligibility is determined by age at the time of administration. Infants born during the RSV season should receive nirsevimab within 1 week of birth. This can be given either in the hospital before discharge or at the doctor’s office after discharge. Those with a prolonged hospital stay should get it shortly before or promptly after discharge. In tropical climates and Alaska where the RSV season may be different than the rest of the US, clinicians should consult state, local or territorial guidance on timing.